BBI prevented the interaction of β-catenin and BCL9 in tumor cells, inhibited the activation of the canonical Wnt/β-catenin signaling pathway, thereby inhibiting the growth of tumor cells and recruiting more CD8+ T cells to act on the tumor (Figure 1). The gene discussed is BCL9; the disease is neoplasm.